Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting

Recent advancements in menin inhibitors for relapsed or refractory acute myeloid leukemia (AML) were a focal point at the 2023 ASH Annual Meeting. Among the highlights, revumenib demonstrated exceptional efficacy, achieving a 100% overall response rate (ORR) when used in combination with decitabine/cedazuridine and venetoclax. These results emphasize Ziftomenib the transformative potential of menin inhibitors in AML treatment, especially within genetically defined subgroups, offering renewed hope for better patient outcomes. Ongoing research, such as the KOMET-008 study, continues to investigate the synergistic effects of menin inhibitors in combination therapies, shaping the future of AML management strategies.